Gossamer Bio CEO stock options repriced to $0.45

Gossamer Bio, Inc. reported that President & CEO Faheem Hasnain had several existing stock option awards surrendered to the company and replaced as part of a one-time repricing effective on March 19, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Gossamer Bio, Inc. reported that President & CEO Faheem Hasnain had several existing stock option awards surrendered to the company and replaced as part of a one-time repricing effective on March 19, 2026. The repricing reduced the exercise price of each affected option grant to $0.45 per share while keeping all other terms, including vesting schedules and expiration dates, unchanged under the company’s 2019 Incentive Award Plan. Individual grants include, for example, 1,680,000 stock options now exercisable at $0.45 per share expiring in 2036. These are compensation-related derivative transactions rather than open-market share purchases or sales.

Insider Trade Summary

20 transactions reported

Mixed 20 txns

Insider Hasnain Faheem

Role President & CEO

Type	Security	Shares	Price	Value
Disposition	Stock Option (Right to Buy)	1,680,000	$0.00	$0.00
Disposition	Stock Option (Right to Buy)	1,540,000	$0.00	$0.00
Disposition	Stock Option (Right to Buy)	1,312,500	$0.00	$0.00
Disposition	Stock Option (Right to Buy)	437,500	$0.00	$0.00
Disposition	Stock Option (Right to Buy)	544,500	$0.00	$0.00
Disposition	Stock Option (Right to Buy)	544,500	$0.00	$0.00
Disposition	Stock Option (Right to Buy)	650,000	$0.00	$0.00
Disposition	Stock Option (Right to Buy)	325,000	$0.00	$0.00
Disposition	Stock Option (Right to Buy)	47,000	$0.00	$0.00
Disposition	Stock Option (Right to Buy)	43,500	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	1,680,000	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	1,540,000	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	1,312,500	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	437,500	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	544,500	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	544,500	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	650,000	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	325,000	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	47,000	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	43,500	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 7,124,500 contracts (Direct)

Footnotes (2)

F1. Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.
F2. This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Gossamer Bio (GOSS) disclose about Faheem Hasnain’s stock options?

Gossamer Bio disclosed that President & CEO Faheem Hasnain’s existing stock option grants were surrendered and replaced in a one-time repricing. The affected options now carry a unified exercise price of $0.45 per share under the 2019 Incentive Award Plan.

When was the Gossamer Bio CEO stock option repricing effective?

The stock option repricing for Gossamer Bio’s CEO was effective on March 19, 2026, referred to as the “Repricing Date.” From that date, all specified Repriced Options carried the reduced exercise price, with other terms and vesting provisions remaining in effect as previously established.

What is the new exercise price of the repriced Gossamer Bio options?

The repriced Gossamer Bio stock options now have an exercise price of $0.45 per share. This reduced price applies to each Repriced Option, while their original vesting schedules and expiration dates, such as grants expiring in 2036, were left unchanged under the 2019 Plan.

Do the repriced Gossamer Bio (GOSS) options change vesting terms?

The repricing did not change vesting terms for Gossamer Bio options. Footnotes state all other provisions, including vesting and option term, remain in full force, following the schedules previously reported and subject to the CEO’s continued service with the company.

Are the Gossamer Bio CEO option transactions open-market trades?

The CEO’s option transactions are not open-market trades. They are classified as derivative dispositions to the issuer and corresponding grants under the 2019 Incentive Award Plan, reflecting a compensation-related repricing rather than buying or selling common shares in the market.

Under which plan were the Gossamer Bio repriced options granted?

All repriced stock options for Gossamer Bio’s CEO were issued under the company’s 2019 Incentive Award Plan. The filing states these awards follow vesting schedules specified in related award agreements and prior reports, conditioned on the executive’s continued service with the issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/20/2026 - 04:17 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hasnain Faheem

(Last)

(First)

(Middle)

3115 MERRYFIELD ROW, SUITE 120

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Gossamer Bio, Inc. [ GOSS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$2.88	03/19/2026		D⁽¹⁾			1,680,000	⁽²⁾	01/01/2036	Common Stock	1,680,000	⁽¹⁾	0	D
Stock Option (Right to Buy)	$1.13	03/19/2026		D⁽¹⁾			1,540,000	⁽²⁾	03/03/2035	Common Stock	1,540,000	⁽¹⁾	0	D
Stock Option (Right to Buy)	$0.97	03/19/2026		D⁽¹⁾			1,312,500	⁽²⁾	01/01/2034	Common Stock	1,312,500	⁽¹⁾	0	D
Stock Option (Right to Buy)	$0.838	03/19/2026		D⁽¹⁾			437,500	⁽²⁾	11/19/2033	Common Stock	437,500	⁽¹⁾	0	D
Stock Option (Right to Buy)	$1.21	03/19/2026		D⁽¹⁾			544,500	⁽²⁾	03/19/2033	Common Stock	544,500	⁽¹⁾	0	D
Stock Option (Right to Buy)	$2.16	03/19/2026		D⁽¹⁾			544,500	⁽²⁾	12/06/2032	Common Stock	544,500	⁽¹⁾	0	D
Stock Option (Right to Buy)	$11.94	03/19/2026		D⁽¹⁾			650,000	⁽²⁾	01/05/2032	Common Stock	650,000	⁽¹⁾	0	D
Stock Option (Right to Buy)	$9.79	03/19/2026		D⁽¹⁾			325,000	⁽²⁾	02/25/2031	Common Stock	325,000	⁽¹⁾	0	D
Stock Option (Right to Buy)	$12.1	03/19/2026		D⁽¹⁾			47,000	⁽²⁾	06/16/2030	Common Stock	47,000	⁽¹⁾	0	D
Stock Option (Right to Buy)	$22.1	03/19/2026		D⁽¹⁾			43,500	⁽²⁾	03/25/2029	Common Stock	43,500	⁽¹⁾	0	D
Stock Option (Right to Buy)	$0.45	03/19/2026		A⁽¹⁾		1,680,000		⁽²⁾	01/01/2036	Common Stock	1,680,000	⁽¹⁾	1,680,000	D
Stock Option (Right to Buy)	$0.45	03/19/2026		A⁽¹⁾		1,540,000		⁽²⁾	03/03/2035	Common Stock	1,540,000	⁽¹⁾	1,540,000	D
Stock Option (Right to Buy)	$0.45	03/19/2026		A⁽¹⁾		1,312,500		⁽²⁾	01/02/2034	Common Stock	1,312,500	⁽¹⁾	1,312,500	D
Stock Option (Right to Buy)	$0.45	03/19/2026		A⁽¹⁾		437,500		⁽²⁾	11/19/2033	Common Stock	437,500	⁽¹⁾	437,500	D
Stock Option (Right to Buy)	$0.45	03/19/2026		A⁽¹⁾		544,500		⁽²⁾	03/19/2033	Common Stock	544,500	⁽¹⁾	544,500	D
Stock Option (Right to Buy)	$0.45	03/19/2026		A⁽¹⁾		544,500		⁽²⁾	12/06/2032	Common Stock	544,500	⁽¹⁾	544,500	D
Stock Option (Right to Buy)	$0.45	03/19/2026		A⁽¹⁾		650,000		⁽²⁾	01/05/2032	Common Stock	650,000	⁽¹⁾	650,000	D
Stock Option (Right to Buy)	$0.45	03/19/2026		A⁽¹⁾		325,000		⁽²⁾	02/25/2031	Common Stock	325,000	⁽¹⁾	325,000	D
Stock Option (Right to Buy)	$0.45	03/19/2026		A⁽¹⁾		47,000		⁽²⁾	06/16/2030	Common Stock	47,000	⁽¹⁾	47,000	D
Stock Option (Right to Buy)	$0.45	03/19/2026		A⁽¹⁾		43,500		⁽²⁾	03/25/2029	Common Stock	43,500	⁽¹⁾	43,500	D

Explanation of Responses:

1. Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

2. This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Remarks:

	/s/ Jeff Boerneke, Attorney-in-Fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR